Oncimmune Ltd. is seeking new distribution partners in the US as it expands the commercialization of its blood-based immunoassay for early-stage lung cancer, the only one of its kind in the market.
The EarlyCDT-Lung test works by measuring autoantibodies that are produced by the body in response to proteins produced by lung...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?